|
|
PHAD |
|
Vaxjo ID |
480 |
|
Vaccine Adjuvant Name |
PHAD |
|
Alternative Names |
Phosphorylated Hexa-Acyl Disaccharide |
|
Adjuvant VO ID |
VO_0005757
|
|
Description |
synthetic TLR4 agonist that induces Th1-biased response |
|
Stage of Development |
Research |
|
Location Licensed |
United States |
|
Host Species for Testing |
Mouse |
|
Components |
monophosphorylated hexa-acylated lipid A |
|
Function |
Type: TLR agonist vaccine adjuvant. Target Receptor: Toll-like receptor 4 (TLR4). Induces Th1-biased immune profile. innate immune activation via TLR4 signaling |
| References |
Haupt et al., 2021: Haupt RE, Harberts EM, Kitz RJ, Strohmeier S, Krammer F, Ernst RK, Frieman MB. Novel TLR4 adjuvant elicits protection against homologous and heterologous Influenza A infection. Vaccine. 2021; 39(36); 5205-5213. [PubMed: 34362603].
|
|
